Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
By G. Attard, A. Reid, T. Yap, F. Raynaud, Mitchell Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd and 6 more. Journal of Clinical Oncology, 2008
886 citations recorded by the source corpus.
Subfields: Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/994aaad605fcdc4627d84d259c7f67e3bd7f6c82
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy (2017, neutral): “(%) Newly diagnosed node‐negative, nonmetastatic disease 256 (27) 253 (26) Newly diagnosed node‐positive, nonmetastatic disease 187 (20) 182 (19) Newly diagnosed metastatic disease 476 (50) 465 (48) Previously treated nonmetastatic disease 12 (1) 25 (3) Previously treated metastatic disease 26 (3) 3”
- Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants (2011, positive): “Though hypothesized, this is the first demonstration that the efficacy of abiraterone is related to its ability to suppress tumor androgen levels and complements previously published data from phase I studies regarding suppression of serum androgens (15, 41).”
- Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011, neutral): “Hypokalemia 135 (17) 27 (3) 3 (<1) 33 (8) 3 (1) 0”